Mr. Andreas Bergsten was Chief Executive Officer of Mertiva AB since April 22, 2013. He has also been Member of the Board of Directors of the Company since February 21, 2014. He is consultant in finance and business management and has, in his capacity as a consultant, primarily worked for VC and private equity firms. In the past, he has served as Chief Financial Officer of four different companies and, prior to this, he was employed at Citigroup, initially as a financial analyst and subsequently as a relationship manager. He is employed as CEO of GForvaltning. He holds a MS degree in Business Administration and Economics from the Stockholm School of Economics and the McGill University MBA Program.
Age: 50 CEO Since 2014 MBA
Management EfficiencyThe company has return on total asset (ROA) of (0.1) % which means that it has lost $0.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 153.09 % meaning that it generated $153.09 on every $100 dollars invested by stockholders.
Entity SummaryMertiva AB , through its interest in Mercodia AB, develops, manufactures, and distributes ELISA assays in the areas of diabetes, obesity, and cardiovascular diseases. Mertiva AB was founded in 1994 and is based in Stockholm, Sweden. Mertiva AB is traded on OTC Market in USA.Mertiva AB (DMYDF) is traded on OTC Market in USA and employs 7 people.
Mertiva AB Management Team
Stock Performance Indicators
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
|All Next||Launch Module|
Additionally see Investing Opportunities. Please also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.